On October 4, 2009
Chelsea and Catalyst Roll the Dice on Re-Analyses, Investors Take the Bet
Chelsea Therapeutics and Catalyst Pharmaceutical Partners both enjoyed nice stock bumps last week thanks to re-analyses of failed clinical trials, even though such analyses often prove to be nothing but trouble for biotechs.
0 Comments